What is the recommended dosage of caspofungin for treating fungal infections?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 1, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Caspofungin Dosing Recommendations

The standard recommended dosage of caspofungin for treating fungal infections in adults is a 70 mg loading dose on day 1, followed by 50 mg daily administered by slow IV infusion over approximately 1 hour. 1

Adult Dosing by Indication

Invasive Candidiasis/Candidemia

  • Administer a single 70 mg loading dose on day 1, followed by 50 mg once daily 1
  • Continue treatment for at least 14 days after the last positive culture and resolution of symptoms 2
  • For infections due to C. parapsilosis, fluconazole or lipid formulation of amphotericin B may be preferred as initial therapy, though continuing caspofungin is reasonable if the patient is clinically stable 2

Invasive Aspergillosis

  • Administer a single 70 mg loading dose on day 1, followed by 50 mg once daily 1
  • Indicated for patients with probable or proven invasive aspergillosis that is refractory to or intolerant of other approved therapies 2
  • Duration of treatment should be based on severity of underlying disease, recovery from immunosuppression, and clinical response 1

Esophageal Candidiasis

  • 50 mg once daily for 7-14 days after symptom resolution (no loading dose needed for this indication) 1

Empirical Therapy for Presumed Fungal Infections

  • Administer a single 70 mg loading dose on day 1, followed by 50 mg once daily 1
  • Continue until resolution of neutropenia and for at least 7 days after both neutropenia and clinical symptoms are resolved 1

Pediatric Dosing (3 months to 17 years)

  • Single 70 mg/m² loading dose on day 1, followed by 50 mg/m² once daily 1
  • Maximum loading dose and daily maintenance dose should not exceed 70 mg, regardless of calculated dose 1
  • Caspofungin at 50 mg/m²/day in children provides exposure comparable to 50 mg/day in adults 2

Dosage Adjustments

Hepatic Impairment

  • No dose adjustment needed for mild hepatic impairment (Child-Pugh score 5-6) 1
  • For moderate hepatic impairment (Child-Pugh score 7-9), reduce maintenance dose to 35 mg daily (still use 70 mg loading dose on day 1) 1
  • No clinical experience in adult patients with severe hepatic impairment or in pediatric patients with any degree of hepatic impairment 1

Renal Impairment

  • No dose adjustment required for renal impairment, including acute kidney injury 3
  • Unlike many other antimicrobials, caspofungin can be administered at standard doses without concern for toxicity due to accumulation in renal impairment 3

Special Considerations

Higher Dose Regimens

  • If the 50 mg dose is well tolerated but does not provide adequate clinical response, the daily dose can be increased to 70 mg 1
  • Higher doses of caspofungin (up to 150-200 mg daily) have been studied and found to be well-tolerated with linear pharmacokinetics across this dosage range 4, 5
  • Maertens et al. reported using higher doses of caspofungin (70 mg/day) for salvage combination therapy of invasive aspergillosis 2

Drug Interactions

  • Caspofungin has minimal potential for drug interactions mediated by the CYP450 enzyme system 2
  • Caspofungin can reduce the area under the curve of tacrolimus by ~20% 2
  • Cyclosporine increases the area under the curve of caspofungin by ~35%; concomitant use should be done with caution due to transient elevations of hepatic aminotransferase levels 2
  • Inducers of drug clearance (efavirenz, nelfinavir, nevirapine, phenytoin, rifampin, dexamethasone, carbamazepine) may reduce caspofungin concentrations 2

Common Adverse Effects

  • Generally well tolerated with few discontinuations due to adverse events 2
  • Most common adverse effects include increased liver aminotransferase levels, gastrointestinal upset, and headaches 2
  • Potential for histamine release, though histamine-like symptoms are rare and may be related to rapid infusion rates 2

Administration

  • Administer by slow IV infusion over approximately 1 hour 1
  • Do not administer by IV bolus 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Caspofungin Dosing in Acute Kidney Injury

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.